Sociedad Americana de Hirudoterapia

Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?.

Research article published in Circulation journal : official journal of the Japanese Circulation Society (2016)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyEnsayos clínicosEsteve-Pastor et al. · Circulation journal : official journal of the Japanese Circulation Society, 2016

Abstract

BACKGROUND: Several bleeding risk scores have been validated in patients with atrial fibrillation (AF). The ORBIT score has been recently proposed as a simple score with the best ability to predict major bleeding. The present study aimed to test the hypothesis that the ORBIT score was superior to the HAS-BLED score for predicting major bleeding and death in "real world" anticoagulated AF patients. METHODS AND RESULTS: We analyzed the predictive performance for bleeding and death of 406 AF patients who underwent 571 electrical cardioversion procedures and 1,276 patients with permanent/persistent AF from the FANTASIIA registry. In the cardioversion population, 21 patients had major bleeding events and 26 patients died. The predictive performance for major bleeding of HAS-BLED and ORBIT were not significantly different (c-statistics 0.77 (95% CI 0.66-0.88) and 0.82 (95% CI 0.77-0.93), respectively; P=0.080). For the FANTASIIA population, 46 patients had major bleeding events and 50 patients died. The predictive performances for major bleeding of HAS-BLED and ORBIT were not significantly different (c-statistics 0.63 (95% CI 0.56-0.71) and 0.70 (95% CI 0.62-0.77), respectively; P=0.116). For death, the predictive performances of HAS-BLED and ORBIT were not significantly different in both populations. The ORBIT score categorized most patients as "low risk". CONCLUSIONS: Despite the original claims in its derivation paper, the ORBIT score was not superior to HAS-BLED for predicting major bleeding and death in a "real world" oral anticoagulated AF population. (Circ J 2016; 80: 2102-2108).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMulticenter Study
Indexed MeSH termsAgedAged, 80 and overAtrial FibrillationElectric CountershockFemaleHemorrhageHumansMaleMiddle AgedPredictive Value of TestsRegistriesRisk Assessment

Resumen

Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?.

Por qué esto importa para la hirudoterapia

Este estudio de validación evaluó si la puntuación de riesgo de hemorragia ORBIT superaba a HAS-BLED en pacientes con fibrilación auricular anticoagulados del mundo real en una cohorte de cardioversión y en el registro FANTASIIA, y no encontró ninguna diferencia estadísticamente significativa entre ambas puntuaciones para predecir hemorragia mayor o muerte. Su relevancia para la hirudoterapia es indirecta y contextual: pertenece a la literatura sobre anticoagulación sistémica y riesgo de hemorragia que ASH recopila para situar la narrativa del secretoma de la sanguijuela dentro de la práctica antitrombótica convencional, pero no aborda la terapia con sanguijuelas, hirudin, ni ningún compuesto derivado de la sanguijuela. La advertencia apropiada es que se trata de un estudio observacional de modelado predictivo sobre puntuaciones de riesgo en pacientes con FA, sin ninguna relación con la eficacia o seguridad de la terapia con sanguijuelas medicinales.

Citación

Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?.

Esteve-Pastor et al. · Circulation journal : official journal of the Japanese Circulation Society, 2016

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.